Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 15,031 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Retinal Vein Occlusions
Interventions: Avastin, Osurdex; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Coronary Artery Disease
Interventions: TAXUS Liberté-SR, TAXUS™ Express; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 40
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 36 more

Conditions: Pulmonary Embolism
Interventions: Contrast-enhanced chest CT; Diagnostic Test
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT; Drug · Other
Lead sponsor: Hearn Jay Cho; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Urticaria
Interventions: TEV-45779, XOLAIR® Injection; Combination Product
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more

Conditions: Pulmonary Hypertension
Interventions: 11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, Cardiac MRI; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Critical Limb Ischemia (CLI), Peripheral Vascular Disease (PVD)
Interventions: Magellan®; Device
Lead sponsor: Arteriocyte, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hemodialysis Access Failure
Interventions: The three-dimensional (3D) printed hemodialysis vascular model; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Cranberry juice; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Hypercholesterolaemia, Hypertension, Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Heart Failure, CAD - Coronary Artery Disease, Stroke Risk, Cardiac Arrythmias, Genetics Hypertension, Genetics, Pharmacogenomics, Pharmacogenomic Testing for Medication Management, Cancer Genetics
Interventions: Color Genomics Genetic Testing Panels; Genetic
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Difficult Intravenous Access in Pediatrics
Interventions: Ultrasound guidance, Traditional intravenous access; Procedure
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypertension
Interventions: olmesartan medoxomil + hydrochlorothiazide, if necessary, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 29
States / cities: Birmingham, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 26 more

Conditions: Venous Leg Ulcer, Chronic Non-Healing Cutaneous Wounds, VLU
Interventions: LUT017 gel; Drug
Lead sponsor: Antoni Ribas; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Carotid Stenosis, Constriction, Pathologic, Carotid Artery Diseases, Cerebrovascular Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Arterial Occlusive Diseases, Vascular Diseases, Cardiovascular Diseases, Pathological Conditions, Anatomical
Interventions: Gore Flow Reversal System, Gore Embolic Filter; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 1,397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 39
States / cities: Flagstaff, Arizona • Newport Beach, California • San Francisco, California + 34 more

Conditions: Cardiovascular Diseases, Vascular Dilation, Oxidative Stress
Interventions: Low Flavanol Cocoa Powder, High Flavanol Cocoa Powder, Vine to Bar Chocolate - 2 servings, Vine to Bar Chocolate - 1 serving, Vine to Bar Chocolate covered almonds; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 30 Years to 50 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Davis, California

Conditions: Subarachnoid Hemorrhage
Interventions: Spinal catheter insertion with extracorporeal filtration of CSF; Device
Lead sponsor: Minnetronix; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Minneapolis, Minnesota • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Intracranial Hemorrhage Ruptured Aneurysm
Interventions: surgical management, Endovascular management; Procedure
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM); Other
Eligibility: 18 Years and older
Enrollment: 1,724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions: Inhaled Treprostinil, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 96
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more

Conditions: Chronic Kidney Disease, Endstage Renal Disease
Interventions: Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG); Procedure
Lead sponsor: Columbia University; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Iberdomide, Lenalidomide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 44
States / cities: Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more

Conditions: Vascular Diseases
Interventions: Placebo, BMS-582949, Atorvastatin, Statin; Other · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 17
States / cities: Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more

Conditions: Alzheimer Disease, Dementia, Dementia, Vascular, Pain
Interventions: hydrocodone/APAP w placebo PRN, hydrocodone/APAP, placebo with hydrocodone/APAP PRN; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Tuscaloosa, Alabama

Search by objective public record fields.

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions

Quantitative 3-Dimensional Chest CT Vascular Reconstruction Before and After Anticoagulation for Pulmonary Embolism

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

Three-dimensional (3D) Printed Hemodialysis Vascular Model

Effect of Cranberry Juice on Endothelial Function

The Effect of Providing Genetic Risk Information on Lifestyle Behaviors in African Americans

Ultrasound Guided IV Access in a Pediatric Emergency Department

Hypertension in Management of Military Medicine

A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults

GORE Flow Reversal System and GORE Embolic Filter Extension Study

Chardonnay Marc and Vascular Response

Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter

International Subarachnoid Aneurysm Trial II

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)